Solventum Co. (NYSE:SOLV) Stock Position Raised by Natixis Advisors LLC

Natixis Advisors LLC boosted its position in shares of Solventum Co. (NYSE:SOLV) by 14.3% during the 4th quarter, HoldingsChannel reports. The firm owned 54,406 shares of the company’s stock after buying an additional 6,790 shares during the quarter. Natixis Advisors LLC’s holdings in Solventum were worth $3,594,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Modus Advisors LLC purchased a new position in shares of Solventum during the fourth quarter valued at $25,000. Stonebridge Financial Group LLC acquired a new stake in Solventum during the 4th quarter worth about $26,000. True Wealth Design LLC grew its stake in Solventum by 23,550.0% during the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new position in shares of Solventum in the 4th quarter valued at about $32,000. Finally, Prospera Private Wealth LLC purchased a new stake in shares of Solventum in the third quarter worth approximately $35,000.

Analysts Set New Price Targets

A number of brokerages recently commented on SOLV. Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Mizuho lifted their price objective on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Finally, Piper Sandler lifted their price target on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Stock Performance

Shares of SOLV opened at $74.00 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The company’s fifty day moving average price is $75.17 and its 200 day moving average price is $71.56. The company has a market capitalization of $12.80 billion and a PE ratio of 26.91.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.